Duke Street Bio announces first patient dosed in Phase I trial with DSB2455, a next deneration PARP1 selective inhibitor for the treatment of solid tumours
December 3, 2024
December 3, 2024
November 14, 2024
November 8, 2024
September 26, 2024
September 24, 2024
September 18, 2024
August 12, 2024
July 23, 2024
July 22, 2024
December 3, 2024
Duke Street Bio Ltd, a precision medicine biotech developing next generation small molecule cancer therapies, is pleased to announce that the first pa...
November 27, 2024
Tillotts Pharma AG (“Tillotts”), which is part of the Japanese Zeria Group, and Pioneer Pharma (Hong Kong) Co., Limited (先鋒醫藥(香港)有限公司) (“Pioneer”), wh...
November 19, 2024
Sakura Finetek Europe and MEDIPATH, a group of independent French pathologists, announced their collaboration to enhance cancer diagnostics and thus c...
Life Science Newswire is a division of BioStrata Ltd, with company registered address: 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, England, WA14 2DT. Company registration number: 8233225